What is Theriva Biologics Inc. (TOVX) stock price today?

Theriva Biologics Inc. (TOVX) currently trades at $0.36 per share. The stock has a market capitalization of $16.23M and a P/E ratio of —x.

Is TOVX stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Theriva Biologics Inc. has a Smart Value Score of 23/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is -13.67.

What is the TOVX stock price target for 2026?

WallStSmart's 12-month price target for Theriva Biologics Inc. is $0.19.

Is Theriva Biologics Inc. financially healthy?

Theriva Biologics Inc.'s Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of -13.67 places it in the distress.

TOVX

Theriva Biologics Inc.

NYSE MKT: TOVX · HEALTHCARE · BIOTECHNOLOGY

$0.36

+8.67% today

Updated 2026-04-30

Market cap

$16.23M

P/E ratio

—

P/S ratio

22.32x

EPS (TTM)

$-2.08

Dividend yield

—

52W range

$0 – $1

Volume

31.8M

Market cap

$16.23M

P/E ratio

—

P/S ratio

22.32x

EPS (TTM)

$-2.08

Dividend yield

—

52W range

$0 – $1

Volume

31.8M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

4.0

Quality

3.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

-13.7

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$2.50

+597.16%

12-Month target

$0.19

-47.02%

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy1 Buy1 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.41x — low leverage

Risks

- Piotroski 2/9 — weak financial health

- Altman Z -13.67 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-2.88M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-19.68M	$-18.35M	$-25.65M	$-25.25M	$-3.51M
EPS	—	—	—	—	$-2.08
Free cash flow	$-19.20M	$-19.20M	$-16.94M	$-16.70M	$-2.88M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
TOVX	$16.23M	23	4.3	3.0	5.0	4.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Theriva Biologics Inc. trades at $0.36. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -13.67, it sits in the distress.

Frequently asked questions

What is Theriva Biologics Inc.'s stock price?

Theriva Biologics Inc. (TOVX) trades at $0.36.

Is Theriva Biologics Inc. overvalued?

Smart Value Score 23/100 (Grade F, Strong Sell).

What is the price target of Theriva Biologics Inc. (TOVX)?

The analyst target price is $2.50, representing +597.2% upside from the current price of $0.36.

Piotroski F-Score?

2/9 — weak financial health.

Altman Z-Score?

-13.67 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNYSE MKT

CurrencyUSD

therivabio.com

Quick metrics

P/S ratio22.32x

ROE-137.80%

Beta0.47

50D MA$0.23

200D MA$0.30

Shares out0.05B

Float0.05B

Short ratio—

Avg volume31.8M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

TOVX vs LLY →TOVX vs JNJ →TOVX vs ABBV →Stock screener →